Labetalol Stragen (Labetalol Hydrochloride)

• Labetalol is used to manage conditions related to elevated blood pressure and vascular resistance.
• Hypertension: lowers systemic blood pressure by reducing cardiac output and peripheral vascular resistance.
• Hypertensive emergencies: provides rapid blood pressure control in acute, life‑threatening situations.
• Acute severe hypertension: stabilises patients with sudden, marked elevations in arterial pressure.

• Labetalol acts as a non‑selective β‑adrenergic antagonist while also blocking α1‑adrenergic receptors. The combined β‑blockade reduces heart rate and myocardial contractility, decreasing cardiac output, whereas α1‑blockade causes vasodilation, lowering peripheral vascular resistance. Together these actions result in a net reduction of arterial blood pressure.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Nausea or vomiting
• Fatigue or weakness
• Flushing or warmth sensation
• Tachycardia or palpitations

Serious or Rare Side Effects

• Severe hypotension leading to syncope
• Bronchospasm, especially in patients with asthma
• Hepatic dysfunction or elevated liver enzymes
• Heart block or severe bradyarrhythmias
• Anaphylactic or severe allergic reactions
• Acute heart failure or pulmonary edema

Labetalol should be used with clinical monitoring and awareness of specific safety considerations.

• Blood pressure monitoring: check frequently during initiation and dose adjustments.
• Asthma or chronic obstructive pulmonary disease: use cautiously due to potential bronchospasm.
• Abrupt discontinuation: avoid sudden stop to prevent rebound hypertension.
• Hepatic impairment: consider dose reduction and monitor liver function.
• Diabetes: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms.
• Store at room temperature: keep in original container, protect from moisture and light.

Labetalol may interact with several drug classes that affect cardiovascular function.

Major Interactions (Avoid)

• Other antihypertensives (e.g., additional β‑blockers, ACE inhibitors) – risk of excessive hypotension.
• Calcium channel blockers such as verapamil – additive negative inotropic effect.
• Monoamine oxidase inhibitors – potential for severe hypertension.
• Clonidine – abrupt withdrawal may cause rebound hypertension.
• Epinephrine or other sympathomimetics – antagonistic effect reducing therapeutic response.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs – may blunt antihypertensive effect.
• Diuretics – monitor electrolytes and blood pressure.
• Antidepressants (SSRIs, SNRIs) – possible additive central nervous system effects.
• Anesthetic agents – may enhance cardiovascular depression.
• Antiarrhythmic drugs – monitor cardiac rhythm for bradyarrhythmias.